PharmaCyte Biotech Accounts Payable

As of the most recent data (January 2026), PMCB shows a accounts payable of $1.2M. That compares with $480K in the prior-year period — up 147.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PMCB's accounts payable is now $1.2M (was $480K) — a 147.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether PharmaCyte Biotech is outperforming or lagging.

Tracking PMCB's accounts payable over time shows whether PharmaCyte Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2M That compares with $480K in the prior-year period — up 147.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has PharmaCyte Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1.2M) with ownership activity and broader fundamentals.

PharmaCyte Biotech's accounts payable is $1.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.